Vemurafenib (PLX4032)

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：Vemurafenib (PLX4032)	Purity：98% min
CAS NO：918504-65-1	Solubility：DMSO: 6.2 mg/mL
Molecular Formula：C₂₃H₁₈ClF₂N₃O₃S	Package：Package according to customer requirements
Molecular Weight：489.922	Storage：Store at -20℃

Quality control

Remarks

Vemurafenib, also known as PLX4032, RG7204 or RO5185426, is an orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib received FDA approval for the treatment of late-stage melanoma on August 17, 2011. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation.

Raf Inhibitors Related Products:

PLX-4720; Debrafenib; Regorafenib; GDC-0879; RAF265 (CHIR-265); AZ-628; SB590885; ZM 336372; TAK-632; B-Raf IN 1; AZ304; Dabrafenib Mesylate; RAF709; LY3009120; RO5126766; Doramapimod; MLN2480; GW5074

References

[1]. Bollag G, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature, 2010, 467(7315), 596-599.

[2]. Yang H, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res, 2010, 70(13), 5518-5527.